Claudia Macaubas

Dr. Claudia Macaubas

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JLJustin Lee
Justin Lee
HTHanson Tam
Hanson Tam
LALital Adler
Lital Adler
AIAlexandra Ilstad-Minnihan
Alexandra Ilstad-Minnihan
CMClaudia Macaubas
Claudia Macaubas
EMElizabeth Mellins
Elizabeth Mellins
Monocytes play a critical role in the innate and adaptive immune systems, performing phagocytosis, presenting antigen, and producing cytokines. They are a heterogeneous population that has been divided in humans into classical, intermediate, and non-classical subsets, but the roles of these subsets are incompletely understood. In this study, we investigated the expression patterns of MHC class II (MHCII) and associated molecules and find that the intermediate monocytes express the highest levels of the MHC molecules, HLA-DR (tested in n = 30 samples), HLA-DP (n = 30), and HLA-DQ (n = 10). HLA-DM (n = 30), which catalyzes the peptide exchange on the MHC molecules, is also expressed at the highest levels in intermediate monocytes. To measure HLA-DM function, we measured levels of MHCII-bound CLIP (class II invariant chain peptide, n = 23), which is exchanged for other peptides by HLA-DM. We calculated CLIP:MHCII ratios to normalize CLIP levels to MHCII levels, and found that intermediate monocytes have the lowest CLIP:MHCII ratio. We isolated the different monocyte subsets (in a total of 7 samples) and analyzed their responses to selected cytokines as model of monocyte activation: two M1-polarizing cytokines (IFNγ, GM-CSF), an M2-polarizing cytokine (IL-4) and IL-10. Classical monocytes exhibit the largest increases in class II pathway expression in response to stimulatory cytokines (IFNγ, GM-CSF, IL-4). All three subsets decrease HLA-DR levels after IL-10 exposure. Our findings argue that intermediate monocytes are the most efficient constitutive antigen presenting subset, that classical monocytes are recruited into an antigen presentation role during inflammatory responses and that IL-10 negatively regulates this function across all subsets.

20 May 2021 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
PCPeggie Cheung
Peggie Cheung
SSSteven Schaffert
Steven Schaffert
SCSarah E. Chang
Sarah E. Chang
MDMai Dvorak
Mai Dvorak
MDMichele Donato
Michele Donato
AKAlex J. Kuo
Alex J. Kuo

31 May 2022 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
GCGuangbo Chen
Guangbo Chen
GDGail H. Deutsch
Gail H. Deutsch
GSGrant S. Schulert
Grant S. Schulert
HZHong Zheng
Hong Zheng
SJSoRi Jang
SoRi Jang
SCScott W. Canna
Scott W. Canna

1 June 1997 in Genome Research
Verified
Journal Article
Open access
PDF file
CMClaudia Macaubas
Claudia Macaubas
LJLi Jin
Li Jin
JHJoachim Hallmayer
Joachim Hallmayer
AKAkinori Kimura
Akinori Kimura
EMEmmanuel Mignot
Emmanuel Mignot
DQCARis a (CA)nmicrosatellite located in the HLA class II region and tightly linked toHLA–DQB1. Previous studies showed a strikingly low level of size variation inDQCARalleles within an extensive subfamily ofHLA–DQsubtypes (DQ1).DQCARalleles in non-DQ1subtypes showed a higher degree of size polymorphism. In this study sequence analysis demonstrates thatDQ1- associatedDQCARalleles have a single C → A nucleotide substitution interupting the CA repeat array. Frequent CA → GA mutations are also observed inDQ1-associated microsatellites with identical allele sizes. In contrast,DQCARalleles associated with non-DQ1haplotypes display a perfect CA repeat sequence and the variation in allele size is attributable only to differences in the number of CA repeats. Our results imply that several mutational mechanisms are involved in the generation of allelic diversity within the same microsatellite locus. The possibility of different mutation rates in the same locus should to be taken into account when using these markers in evolutionary and disease studies.[The sequence data described in this paper have been submitted to the GenBank data library under accession nos.U96944–U96962andS87165.]

1 June 2003 in Current Drug Targets - Inflammation & Allergy
Verified
Journal Article
Closed access
PDF file
CMClaudia Macaubas
Claudia Macaubas
RDRosemarie H. DeKruyff
Rosemarie H. DeKruyff
DUDale T. Umetsu
Dale T. Umetsu
Understanding the pathways involved in the induction and maintenance of respiratory tolerance to airborne allergens is important in designing new therapies for asthma and other allergic diseases that not only control disease symptoms, but also change or potentially cure the disease. Respiratory tolerance, and mucosal immunity are maintained by a complex system of defense mechanisms. Most of the inhaled environmental load is eliminated by exclusion mechanisms, which include physical barriers, such as mucus, and cilia as well as a variety of mediators with anti-microbial and immunomodulatory properties. Blanket immunosuppression is provided by alveolar macrophages, which inhibit antigen presentation and T cell responses, in addition to their role in pathogen elimination. Furthermore, there is antigen specific unresponsiveness or tolerance. This tolerance is mediated by lung dendritic cells producing IL-10, which induce the development of CD4+ T regulatory cells. The development of respiratory tolerance also depends on co-stimulation (CD86, and the ICOS-ICOSL pathway). Although exposure of the respiratory mucosa to some pathogenic agents (especially virus, and endotoxin) is associated with asthma exacerbations, microbial exposure may also promote mucosal tolerance and protection against the development of allergic diseases, but the mechanisms involved are not very well understood. Mucosal-based immunotherapy has been already used as an alternative form of allergen delivery in immunotherapy, the only available treatment that is able to reverse established allergic disease. Strategies to further improve mucosal immunotherapy include the use of modified allergen derived peptides, and adjuvants like CpG motifs.

4 May 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
XZXiaoying Zhou
Xiaoying Zhou
WYWong Yu
Wong Yu
SLShu-Chen Lyu
Shu-Chen Lyu
CMClaudia Macaubas
Claudia Macaubas
BBBryan Bunning
Bryan Bunning
Kari NadeauKari Nadeau
Kari Nadeau
Food allergies are a leading cause of anaphylaxis, and cellular mechanisms involving antigen presentation likely play key roles in their pathogenesis. However, little is known about the response of specific antigen-presenting cell (APC) subsets to food allergens in the setting of food allergies. Here, we show that in peanut-allergic humans, peanut allergen drives the differentiation of CD209+ monocyte-derived dendritic cells (DCs) and CD23+ (FcєRII) myeloid dendritic cells through the action of allergen-specific CD4+ T cells. CD209+ DCs act reciprocally on the same peanut-specific CD4+ T cell population to reinforce Th2 cytokine expression in a positive feedback loop, which may explain the persistence of established food allergy. In support of this novel model, we show clinically that the initiation of oral immunotherapy (OIT) in peanut-allergic patients is associated with a decrease in CD209+ DCs, suggesting that breaking the cycle of positive feedback is associated with therapeutic effect.